Utility and safety of a new uneven double-lumen sphincterotome in cases of difficult biliary cannulation

Shuhei Shintani1, Osamu Inatomi1*, Yoshiya Takeda1, Hiroshi Matsumoto1, Takehide Fujimoto1, Yoshihisa Tsuji2, Hiromu Kutsumi3 and Akira Andoh1

Abstract

Background: We investigated the utility and safety of a new uneven double-lumen sphincterotome in biliary cannulation in comparison with the conventional pancreatic guidewire (PGW) method.

Methods: We retrospectively evaluated 119 patients who required PGW placement because of difficult biliary cannulation. Endoscopic retrograde cholangiopancreatography (ERCP) was performed using a conventional ERCP catheter or a new uneven double-lumen sphincterotome. The success rate of bile duct cannulation, the operation time of bile duct cannulation, and the incidence of post-ERCP pancreatitis (PEP) were evaluated.

Results: Forty-four patients were treated with a new double-lumen sphincterotome (the new sphincterotome group) and 75 patients underwent conventional PGW placement (the conventional group). The success rate of bile duct cannulation was 39/44 (88.6%) in the new sphincterotome group and 63/75 (84.0%) in the conventional group (not significant). The total biliary cannulation time (from the reach to the papilla to the finish of biliary cannulation) was 16.0 (6.5–78) min in the new sphincterotome group and 26.0 (5–80) min in the conventional group (P < 0.01). The time from PGW placement to bile duct cannulation was 3.5 (0.3–57) min in the magictome group and 12.0 (1–65) min in the conventional group (P < 0.01). Hyperamylasemia was observed in 13/44 (29.5%) and 17/75 (22.7%), respectively (not significant). Five of 44 (11.3%) of the new sphincterotome group and 14/75 (18.7%) of the conventional group were diagnosed with PEP (not significant).

Conclusion: A new double-lumen sphincterotome allows selective bile duct cannulation to be performed in a shorter time than the conventional PGW method.

Keywords: Sphincterotome, ERCP, Pancreatic guidewire method
to be associated with a risk of PEP due to contrast media injection and/or mechanical injury of the pancreatic duct [8]. PGW placement includes several steps: cannulation into the pancreatic duct to insert a guidewire, pull off the pancreatic cannula while retaining the guidewire, and cannulation or guidewire insertion into the bile duct [9]. These processes are somewhat complicated and time consuming. Moreover, placed PGW sometimes disturbs next approach to the common bile duct.

MagicTome® (Piolax Inc., Yokohama, Japan) is a new double-lumen sphincterotome with distal (tip) and proximal (side) holes (Fig. 1). Each lumen is 0.025 inch in diameter. The distance between the distal and proximal holes is 17 mm. This device allows PGW placement and bile duct cannulation without the need to change any devices. This may shorten total procedure time and improve the success rate of selective biliary cannulation. In 2018, we changed the cannulation method from conventional PGW placement using a single-lumen catheter to MagicTome®. In this study, we investigated whether MagicTome® reduces the operation time and alters the incidence of PEP after PGW placement.

Methods

Patients

From January 2013 to February 2020, 1,311 patients underwent ERCP at the Shiga University of Medical Science Hospital. Of these, we retrospectively evaluated 119 patients who required PGW placement because of difficult bile duct cannulation (a conventional cannulation into the bile duct needing more than 10 min or 10 unsuccessful attempts). ERCP was performed using a conventional ERCP catheter (MTW ERCP catheter: ABIS, Tokyo, Japan) from January 2013 to May 2018 (the conventional group) and the MagicTome® sphincterotome (Piolax) from June 2018 to February 2020 (the magictome group). Patients with a history of endoscopic sphincterotomy (EST), Billroth II surgery or pancreatic disease were excluded. All data related to ERCP was stored as a video and electronic database. All patients provided a written informed consent prior to undergoing ERCP. This study was approved by the ethics committee of the Shiga University of Medical Science (No. R2019-115). A trainee was defined as an operator who had performed fewer than 100 ERCP procedures within 5 years.

Endoscopic procedure

A combination of midazolam and pentazocine were used for conscious sedation in all patients until 2014, and dexmethomidine was added from 2015. ERCP was conducted with a side-viewing duodenoscope JF260V (Olympus Optical Co., Tokyo, Japan) and an ERCP guidewire Visiglide2® (Olympus). A pancreatic duct stent (Geenen® 5Fr, Cook Medical, Tokyo, Japan) was applied if the operator required it in cases where EST was not performed. When performing the PGW placement, pancreatography was performed using a minimal amount of contrast injection. After confirming the clearance of contrast media from the pancreatic duct, a guidewire was inserted into the deep pancreatic duct.
When PGW placement did not successfully achieve biliary cannulation, a precut sphincterotomy or another maneuver was performed.

**Selective bile duct cannulation using a double-lumen sphincterotome**

MagicTome® (Piolax) is a sphincterotome knife with a double lumen at the tip and side holes. The pancreatic duct is fixed by the guidewire from the proximal (side) hole, and the bile duct and pancreatic duct are separated by raising the catheter tip. This enables subsequent bile duct cannulation from the distal (tip) hole. A schema of the typical process is presented in Fig. 2. (a) The operator inserts the guidewire into the pancreatic duct from the distal (tip) hole. (b) Then, the operator should slightly place the catheter into the pancreatic duct and insert another guidewire in the pancreatic duct from the proximal (side) hole. (c) The operator pulls the tip of the guidewire into the catheter, and then pulls the catheter back to the duodenum while retaining the pancreas guidewire. (d) The approach to the papilla and bile duct can be performed from the duodenum. This method does not require the exchange or removal of any devices during the procedure.

**Outcome**

We investigated the success rate of bile duct cannulation, the operation time and the incidence of PEP of the biliary cannulation using MagicTome® in comparison with the conventional method using a single-lumen catheter.

**Safety evaluation**

Hyperamylasemia, PEP, bleeding, perforation, and cholangitis were evaluated as complications. Diagnosis and disease severity of PEP were based on the criteria of Cotton et al. [4]. These include newly developed abdominal pain and elevation of serum amylase levels 3 times over the upper limit of normal level within 24 h [4].

**Statistical analysis**

The continuous variables pertaining to the baseline characteristics of the two groups were compared by using the Student’s t-test or the Wilcoxon rank-sum test, as appropriate. Categorical variables were compared using the chi-square or Fisher’s exact test. Values of $p < 0.05$ were considered to be significantly different. Multivariate analysis was performed on factors that had $p < 0.10$ in the univariate analysis. All statistical analyses were performed using EZR version 1.40 (Jichi Medical University, Shimosu, Japan).

**Results**

There were no significant differences in patients’ characteristics between the magicTome group and the conventional group (Table 1).

Of 119 patients who underwent PGW placement, 44 patients were treated with MagicTome® (the magicTome group) and 75 patients underwent conventional PGW placement (the conventional group) (Fig. 3). The success rate of bile duct cannulation was 39/44 (88.6%) in the magicTome group and 63/75 (84.0%) in the conventional group (no significant difference) (Table 2). Of 5 patients with bile duct cannulation failure in the magicTome group, 3 patients subsequently received precut sphincterotomy, but bile duct cannulation was a failure in 2 patients. In the conventional group, bile duct cannulation was unsuccessful in 12 patients, and 7 patients were successfully cannulated after precut sphincterotomy (Fig. 3).

The total biliary cannulation time (from the reach to the papilla to the finish of bile duct cannulation) was 16.0 (6.5–78) min in the magicTome group and 26.0 (5–80) min in the conventional group ($P < 0.01$) (Table 2). The time from PGW placement to biliary cannulation was 3.5 (0.3–57) min in the magicTome group and 12.0 (1–65) min in the conventional group ($P < 0.01$).

Placement of a pancreatic duct stent was performed in 10/44 (22.7%) in the magicTome group and 18/75 (24.0%) in the conventional group (no significant difference). Hyperamylasemia was observed in 13/44 (29.5%) of the magicTome group and 17/75 (22.7%) in the conventional group (no significant difference) (Table 2). Five of 44 (11.3%) of the magicTome group and 14/75 (18.7%) of the conventional group were diagnosed with PEP (no significant difference) (Table 2).

**Discussion**

This study revealed a number of important points regarding the use of MagicTome® in selective bile duct cannulation. While MagicTome® significantly shortened the bile duct cannulation time, it did not alter the success rate of the procedure. Complication rates associated with MagicTome® use were comparable to those of the conventional PGW placement.

PGW placement, such as the contrast-medium method and the contrast-free guidewire cannulation method, has been reported to be useful for selective biliary cannulation in patients in whom biliary cannulation is difficult [10]. The PGW method was first reported in 1998 by Dumonceau et al. as useful for biliary cannulation in Billroth I gastrectomy cases [11]. Gotoh et al. reported the usefulness of the double-guidewire method to straighten a tortuous pancreatic duct [12]. Ito et al. reported that 82 out of 113...
(72.6%) patients with difficulties in biliary cannulation were successfully cannulated by PGW placement [10]. However, PGW placement requires the removal of the pancreas catheter while retaining the guidewire left in the pancreatic duct. This step is inconvenient and time-consuming. The placed PGW occasionally disturbs next approach to the common bile duct. Moreover, it is sometimes difficult to insert the catheter or guidewire

Fig. 2 Process of selective bile duct cannulation using MagicTome®. a The guidewire is initially inserted into the pancreatic duct through the distal (tip) hole. b The catheter should be slightly put into the pancreatic duct, and another guidewire inserted into the pancreatic duct from the proximal (side) hole. c The guidewire inserted from the distal (tip) hole should be pulled into the catheter, and the catheter itself pulled back to the duodenum. d The approach to the papilla and bile duct can be performed from the duodenum. This method is characterized by not requiring the exchange or removal of any devices during the procedure. e Fluoroscopic image showing two guidewires in the pancreatic duct. f Fluoroscopic image showing successful bile duct cannulation.
in the direction of the bile duct, which delays biliary cannulation.

In a novel approach, Takenaka et al. recently reported the usefulness of a newly-developed biliary cannulation method for difficult cannulation cases using a unique, uneven, double-lumen cannula (uneven method) [2, 13]. They reported that their cannula straightened the pancreatic duct and the common channel, thereby effectively stabilizing the papilla and enabling easy adjustment of the catheter axis to comply with the bile duct direction.

Table 1  Patients characteristics

|                           | The magictome group | The conventional group | P value |
|---------------------------|---------------------|------------------------|---------|
|                           | n = 44              | n = 75                 |         |
| Age, median (range), year | 72.0 (42–89)        | 74.0 (36–93)           | 0.36    |
| Sex (male/female), n      | 25 /19              | 48/27                  | 0.56    |
| Indication of ERCP, n (%) |                     |                        |         |
| CBD stone                 | 24 (54.5)           | 38 (50.7)              | 0.83    |
| Neoplasm                  | 16 (36.4)           | 22 (29.3)              | 0.56    |
| Others                    | 4 (9.1)             | 15 (20.0)              | 0.13    |
| ASA ≥ 3, n (%)            | 4 (9.1)             | 9 (12.0)               | 0.77    |
| Anticoagulant use, n (%)  | 7 (15.9)            | 17 (22.7)              | 0.52    |
| Duodenum diverticulum, n (%) | 3 (6.8)        | 5 (6.7)                | 1.0     |
| Oral protrusion of the papilla, mm (mean±SD) | 10.4±4.9 | 9.7±2.9 | 0.33 |
| Purpose of ERCP, n (%)    |                     |                        |         |
| EST                       | 27 (61.4)           | 39 (52.0)              | 0.42    |
| EPBD                      | 1 (2.3)             | 6 (8.0)                | 0.26    |
| IDUS                      | 15 (34.1)           | 16 (21.3)              | 0.19    |
| EBD                       | 20 (45.5)           | 31 (41.3)              | 0.81    |
| Biopsy                    | 2 (4.5)             | 3 (4.0)                | 1.0     |
| Cases performed by trainee, n (%) | 22 (50.0)    | 32 (42.7)              | 0.56    |

In this study, we reported a new bile duct cannulation method for difficult cannulation cases using a MagicTome® sphincterotome. Similar to the uneven cannula used by Takenaka et al., MagicTome® is a uneven double-lumen sphincterotome with distal and proximal holes. However, there are several differences in the method of bile duct cannulation between the uneven cannula and MagicTome®. PGW placement using the uneven cannula is initiated via the distal (tip) hole, whereas using the MagicTome® it is placed via the proximal (lateral) hole. The tip of the uneven cannula is inserted and fixed in the pancreatic duct, but MagicTome® can move freely and allows free approach to the papilla or common bile duct. When needed, precut sphincterotomy is easily performed with MagicTome® without any device exchange. Thus, there are a number of differences in bile duct cannulation approach between the uneven cannula and MagicTome®.

The success rate of bile duct cannulation tended to be higher in the magictome group (88.6%) than in the conventional group (84%), but there was no significant difference. The current study was performed in cases of difficult biliary cannulation, and the successful cannulation rate in this study is acceptable when comparing with previous reports [9, 14]. This issue should be prospectively reconfirmed in a multicenter study with much greater number of patients. Both total biliary cannulation time and the time from PGW placement to bile duct cannulation were significantly reduced in the magictome.
Shintani et al. BMC Gastroenterol (2021) 21:102

group compared to the conventional group. These findings indicate that MagicTome® use is effective in shortening the operation time for selective bile duct cannulation in patients where biliary cannulation is difficult. This may be associated with the fact that MagicTome® needs no device exchange. Previously reported effects of PGW placement such as opening a stenotic papillary orifice, stabilizing the papilla and straightening the pancreatic duct and the common channel might be also involved [14]. In addition, its ability to easily adjust its axis to comply with the bile duct direction might contribute to the shortening of operation time. Shortening the operation time may benefit not only the risk of PEP but also complication associated with sedation and radiation exposure of the operators.

Precut sphincterotomy seemed to be ineffective in the magictome group compared to the conventional group. Although the number of patients with unsuccessful biliary cannulation in the magictome group was small (n = 3), such patients might have anatomical constraints that make cannulation particularly difficult.

Many studies reported prophylactic effect of pancreatic duct stent placement on PEP [15, 16]. However, the benefit remains still controversial in terms of the costs and risks associated with approaching the pancreatic duct [17]. Therefore, in the present study, placement of pancreatic duct stent was performed in a limited number of patients. Information bias was minimal as the frequency was comparable between two groups.

The safety of MagicTome® use was confirmed to some extent, since there were no significant differences in the incidence of hyperamylasemia and PEP between the magictome group and the conventional group. Pancreatitis remains the most common complication of ERCP, occurring in 4% to 7% of unselected patients to 30% in high-risk patients [8, 18, 19]. The edema of the papilla caused by repeated cannulation and/or the increased pressure from contrast injection are risk factors for PEP [19]. The influence of PGW placement on PEP remains controversial. PGW placement has been reported to improve the success rate of bile duct cannulation, reduce papillary trauma, and avoid inadvertent contrast injection, thereby reducing the risk of PEP [19]. On the other hand, mechanical injury of the pancreatic duct by PGW has been reported to be a potential risk factor [19], suggesting that the shortening of retaining time of PGW using MagicTome® may reduce the incidence of PEP.

**Conclusions**

The MagicTome® technique is a feasible and safe method in difficult bile duct cannulation avoiding the complicated processes that occur in the conventional PGW method. This was a retrospective, single-center study comparing MagicTome® use with the conventional technique. As such, the usefulness and safety of MagicTome® including the issues other than those assessed in this study should be investigated in a prospective randomized study in the future.

**Abbreviations**

ERCP: Endoscopic retrograde cholangiopancreatography; PGW: Pancreatic guidewire; PEP: Post-ERCP pancreatitis; precut: Precut sphincterotomy; EUS-BD: Endoscopic ultrasound biliary drainage; CBD: Common bile duct; ASA: American Society of Anesthesia Classification; EST: Endoscopic sphincterotomy; EPBD: Endoscopic papillary balloon dilation; IDUS: Intraductal ultrasound sonography; EBD: Endoscopic biliary drainage.

**Acknowledgements**

Not applicable.

Table 2: Outcome and complications

|                                               | The magictome group | The conventional group | P value |
|------------------------------------------------|---------------------|------------------------|---------|
| Successful biliary cannulation, n (%)         | 39 (88.6)           | 63 (84.0)              | 0.67    |
| Procedure time, min, median (range)           |                     |                        |         |
| Total biliary cannulation timea               | 16.0 (6.5–78)       | 26.0 (5–80)            | <0.01   |
| Time from PGW placement to biliary cannulation| 3.5 (0.3–57)        | 12.0 (1–65)            | <0.01   |
| Complications, n (%)                          |                     |                        |         |
| Hyperamylasemia                               | 13 (29.5)           | 17 (22.7)              | 0.54    |
| PEP                                           | 5 (11.4)            | 14 (18.7)              | 0.44    |
| Cholangitis                                   | 3 (6.8)             | 2 (2.7)                | 0.36    |
| Bleeding                                      | 1 (2.3)             | 4 (5.3)                | 0.65    |
| Perforation                                   | 0                   | 1 (1.3)                | 1.0     |
| Placemen of pancreatic duct stent, n (%)      | 10 (22.7)           | 18 (24.0)              | 1.0     |

PEP: post-ERCP pancreatitis
a From the reach to the papilla to the finish of biliary cannulation
Authors’ contributions
SS was involved in analyzing the results and writing the manuscript. YT participated in the design of the study and performed the statistical analysis. YT, HH, and TF helped procedure for ERCP. KY and AA conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Funding
This work was supported by JSPS KAKENHI Grant Number JP18K08002.

Availability of data and materials
The datasets used during the current study available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The study was conducted in agreement with the Declaration of Helsinki and received approval from the ethics committee of Shiga University of Medical Sciences and conformed to its guidelines. All patients provided informed written consent prior to undergoing ERCP.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of General Medicine, The authors declare that they have no competing interests.

References
1. Sasahira N, Kawakami H, Isayama H, Uchino R, Nakai Y, Ito Y, et al. Early use of double-guidewire technique to facilitate selective bile duct cannulation: the multicenter randomized controlled EDUCATION trial. Endoscopy. 2015;47(5):E229–30.
2. Takenaka M, Anisaka Y, Sakai A, Kobayashi T, Shiomi H, Masuda A, et al. A novel biliary cannulation method for difficult cannulation cases using a unique, uneven, double-lumen cannula (uneven method). Endoscopy. 2018;50(8):E229–30.
3. Tanaka R, Itoi T, Sofuni A, Itokawa F, Kurhara T, Tsuchiya T, et al. Is the double-guidewire technique superior to the pancreatic duct guidewire technique in cases of pancreatic duct occlusion? J Gastroenterol Hepatol. 2013;28(11):1787–93.
4. Cotton PB, Lehman G, Vennes J, Geenen JE, Russell RC, Meyers WC, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc. 1991;37(3):383–93.
5. Sherman S, Lehman GA. ERCP- and endoscopic sphincterotomy-induced pancreatitis. Pancreas. 1991;6(3):350–67.
6. Freeman ML, DiSario JA, Nelson DB, Fennerty MB, Lee JG, Bjorkman DJ, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc. 2001;54(4):425–34.
7. Gyokere T, Duhl J, Varsanyi M, Schwab R, Burai M, Pap A. Double guide wire placement for endoscopic pancreaticobiliary procedures. Endoscopy. 2003;35(1):95–6.
8. Hida T, Matsumoto R, Takamatsu M, Furutake M. Impact of changing our cannulation method on the incidence of post-endoscopic retrograde cholangiopancreatography pancreatitis after pancreatic guidewire placement. World J Gastroenterol. 2011;17(48):5289–94.
9. Maeda S, Hayashi H, Hosokawa O, Doihden K, Hattori M, Morita M, et al. Prospective randomized pilot trial of selective biliary cannulation using pancreatic guide-wire placement. Endoscopy. 2003;35(9):721–4.
10. Ito K, Fujita N, Noda Y, Kobayashi G, Obana T, Horaguchi J, et al. Pancreatic guidewire placement for achieving selective biliary cannulation during endoscopic retrograde cholangio-pancreatography. World J Gastroenterol. 2008;14(36):5595–600 (Discussion 9).
11. Dumonceau JM, Deviere J, Cremer M. A new method of achieving deep cannulation of the common bile duct during endoscopic retrograde cholangiopancreatography. Endoscopy. 1998;30(7):S80.
12. Gotoh Y, Tamada K, Tomiyama T, Wada S, Ohhashi A, Satoh Y, et al. A new method for deep cannulation of the bile duct by straightening the pancreatic duct. Gastrointest Endosc. 2001;53(7):820–2.
13. Takenaka M, Yamao K, Kudo M. Novel method of biliary cannulation for patients with Roux-en-Y anastomosis using a unique, uneven, double-lumen cannula (uneven method). Dig Endosc. 2018;30(6):808–9.
14. Ito K, Fujita N, Noda Y, Kobayashi G, Obana T, Horaguchi J, et al. Can pancreatic duct stenting prevent post-ERCP pancreatitis in patients who undergo pancreatic duct guidewire placement for achieving selective biliary cannulation? A prospective randomized controlled trial. J Gastroenterol. 2010;45(11):1183–91.
15. Conigliaro R, Manta R, Bertani H, Manno M, Barbera C, Curaso A, et al. Pancreatic duct stenting for the duration of ERCP only does not prevent pancreatitis after accidental pancreatic duct cannulation: a prospective randomized trial. Surg Endosc. 2013;27(2):569–74.
16. Mazaki T, Mado K, Masuda H, Shiono M. Prophylactic pancreatic stent placement and post-ERCP pancreatitis: an updated meta-analysis. J Gastroenterol. 2014;49(2):343–55.
17. Ryozawa S, Itoi T, Katanuma A, Okabe Y, Kato H, Horaguchi J, et al. Japan Gastroenterological Endoscopy Society guidelines for endoscopic sphincterotomy. Dig Endosc. 2018;30(2):49–73.
18. Mianati A, Giussani A, Di Leo M, Testoni S, Testoni PA. Guidewire biliary cannulation does not reduce post-ERCP pancreatitis compared with the contrast injection technique in low-risk and high-risk patients. Gastrointest Endosc. 2012;75(2):339–46.
19. Thaker AM, Mosko JD, Berzin TM. Post-endoscopic retrograde cholangiopancreatography pancreatitis. Gastroenterol Rep (Oxf). 2015;3(1):32–40.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.